頭頚部がんに対するNK631(Bleomycin誘導体)使用経験

概要

論文の詳細を見る
The clinical effects of NK-631 were studied in 35 cases of malignant tumors of the head and neck. These materials comprised 17 cases of oral carcinoma, 5 of maxillary carcinoma, 5 of hypopharyngeal carcinoma, 4 of mesopharyngeal carcinoma, 3 of laryngeal carcinoma and 1 of skin carcinoma. Of these cases, 16 were newly diagnosed and 19 were recurrent.NK-631 was, in most cases, administered on a dosage schedule of 10mg at a time, 3 times weekly, intramuscularly. The effective rate of NK-631 treatment (by not less than 50% regression in area of mass) in these 35 cases was 39.4%, while the effective rate in the fresh cases was 56.3%. The mean total dose was 92.5mg in the new cases, and 130.5mg in the recurrent cases.In the treatment of primary lesions, a high effective rate was achieved in the cases of oral carcinoma exhibiting exophitic growth.Histologic findings with passage of time indicated that the effects of no less than grade III were achieved in 3 of 7 cases where histologic examinations were possible. However, these findings were not necessarily in parallel with the total doses administered. NK-631 was also found effective in the treatment of metastases to lymph nodes in 2 of the 7 cases.No such severe adverse reaction as pulmonary fibrosis which is occasionally encountered in Bleomycin treatment was observed either clinically or in autopsy: thus, NK-631 was assessed by to be far safer than Bleomycin.
耳鼻咽喉科臨床学会の論文